Previous close | 70.37 |
Open | 70.59 |
Bid | 70.53 x 100 |
Ask | 70.74 x 100 |
Day's range | 70.43 - 72.08 |
52-week range | 49.24 - 94.57 |
Volume | |
Avg. volume | 173,217 |
Market cap | 1.267B |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | 23.29 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 Jul 2010 |
1y target est | N/A |
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.